Pfizer hits the gas pedal in the mRNA flu vaccine development race, inking a $425M investment pact with BioNTech
The mRNA specialists at BioNTech have added another deep-pocket pharma giant to the fold.
Pfizer has stepped up with a $120 million cash commitment …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
